04.08.2020 • NewsAshlandAOCDede Willams

Ashland Sells Maleic Anhydride Portfolio to AOC

US chemical producer Ashland said it has reached a “definitive agreement” to sell its maleic anhydride (MA) business and the production plant at Neal, West Virginia, to AOC Materials for $100 million. The transaction is expected to close by the end of 2020, pending all approvals.

The business was not included in Ashland’s divestment of its composites business and its butanediol (BDO) plant at Marl, Germany, to the Ineos group in September 2019.

Dublin, Ohio-headquartered Ashland reacquired the 40-45,000 t/y West Virginia plant in 2010 from its former partner, Marathon Petroleum, based at Findlay. It had initially sold the facility to Marathon in 2005, along with its share in a former joint venture. It was Ashland’s only MA production asset.

Guillermo Novo, chairman and CEO of Ashland, said the divestment is part of the company’s drive to improve its margins by streamlining its portfolio and focusing on specialty ingredient.

AOC, based at Collierville, Tennessee, is a leading manufacturer of the chemical used as a feedstock for unsaturated polyester resins as well as in other large-scale coatings and polymer applications. Its CEO, Joe Salley, said the company plans to produce the additional MA volumes for its own internal consumption as well as selling some of it on the merchant market.

Ashland is selling its maleic anhydride (MA) portfolio and its plant at Neal,...
Ashland is selling its maleic anhydride (MA) portfolio and its plant at Neal, West Virginia, to AOC Materials for $100 million. The deal is due to close by year’s end. MA was excluded from Ashland’s sale of its composites business and BDO plant at Marl, Germany last year. (c) Ashland

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read